The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease

Table 2

Selective-TLR antagonists in cardiovascular disease.

Compound	Target	Indication	Drug class	Clinical phase	Company
OPN-305	TLR2	Inflammation, autoimmunity,  I/R injury	Antibody	Preclinical	Opsona Therapeutics
Eritoran	TLR4	Sepsis I/R injury (preclinical)	Synthetic lipopolysacharide	Phase III	Eisai Pharmaceuticals
TAK-242	TLR4	Sepsis, inflammation	Small-molecule inhibitor	Discontinued in phase III	Takeda
NI-0101	TLR4	Inflammation, autoimmunity, CVD, I/R injury, and so forth	Antibody	Preclinical	Novimmune
IMO-3100	TLR7 and TLR9	SLE, RA, MS, atherosclerosis	DNA-based compound	Preclinical	Idera Pharmaceuticals

CVD: cardiovascular disease; MS: multiple sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; I/R: ischaemia reperfusion.